Nov 13, 2025 07:51AM Traws Pharma (TRAW) Misses Q3 EPS by 34c

Oct 6, 2025 07:02AM Traws Pharma names John Leaman to board, removes interim CEO and CFO titles

Aug 14, 2025 07:33AM Traws Pharma (TRAW) Misses Q2 EPS by 11c

Jun 30, 2025 06:31AM Traws Pharma (TRAW) Advances Antiviral Pipeline with Multiple Regulatory Submissions

May 27, 2025 08:04AM Traws Pharma (TRAW) Announces Receipt of FDA Guidance on Tivoxavir Marboxil

May 15, 2025 04:39PM Traws Pharma (TRAW) Tops Q1 EPS by 209c

Mar 28, 2025 04:30PM Traws Pharma (TRAW) Announces Management Updates

Mar 25, 2025 07:33AM Traws Pharma (TRAW) COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 24, 2025 07:02AM Traws Pharma (TRAW) Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates

Mar 21, 2025 07:01AM Traws Pharma's (TRAW) Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 3, 2025 07:02AM Traws Pharma (TRAW) Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Feb 28, 2025 07:00AM Traws Pharma (TRAW) Regains Compliance with NASDAQ Equity Listing Rule

Jan 15, 2025 06:35AM Traws Pharma (TRAW) Files for 7.23M Share Offering by Selling Stockholders

Dec 30, 2024 08:01AM Traws Pharma (TRAW) Announces Financing up to $72.6M from Leading Healthcare Institutional Investors

Dec 23, 2024 07:04AM Traws Pharma (TRAW) Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024 05:45PM Traws Pharma, Inc. (TRAW) Misses Q3 EPS by 856c

Oct 8, 2024 07:30AM Traws Pharma (TRAW) Reports Positive Topline Phase 1 Data for Tivoxavir Marboxil

Sep 30, 2024 07:30AM Traws Pharma (TRAW) Reports Positive Topline Phase 1 Results for Ratutrelvir

Sep 20, 2024 07:30AM Traws Pharma (TRAW) Appoints Luba Greenwood to its Board

Jul 1, 2024 04:52PM Traws Pharma (TRAW) Files for 128.94M Share Offering by Selling Stockholders